SLC6A2 and Obesity: In the present study, we have confirmed the therapeutic effect of EA in rats with high-fat diet (HFD)-induced obesity, and have explored the potential neuro-immune mechanisms underlying this effect by examining the expression of the SNS, iWAT, SAMs, NE, β3 adrenergic receptor, UCP1, and Slc6a2 in obese rats that are treated with EA.